Biogen shares slide as guidance cut overshadows Q3 earnings beat By Investing.com
Update: 2025-10-30
Description
Biogen's Q3 results beat expectations with adjusted earnings of $4.81 per share and revenue of $2.53 billion, a 3% increase. However, the company lowered its full-year forecast due to new business development costs. Despite this, Biogen's growth came from new product launches, with LEQEMBI's Alzheimer's drug sales jumping 82% to $121 million. The company predicts flat or slightly increased revenue next year and is advancing its drug pipeline, including resubmitting SPINRAZA's application and planning to share litifilimab's lupus trial results in H2 2026.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
